Sector Gamma AS Makes New Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Sector Gamma AS acquired a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 23,609 shares of the medical research company's stock, valued at approximately $7,623,000. Bio-Rad Laboratories makes up about 1.8% of Sector Gamma AS's holdings, making the stock its 21st biggest holding. Sector Gamma AS owned approximately 0.08% of Bio-Rad Laboratories at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Brio Consultants LLC acquired a new stake in Bio-Rad Laboratories in the fourth quarter valued at about $840,000. Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Bio-Rad Laboratories by 11.2% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 776 shares of the medical research company's stock valued at $251,000 after purchasing an additional 78 shares in the last quarter. Bfsg LLC acquired a new stake in shares of Bio-Rad Laboratories during the fourth quarter valued at about $77,000. Yousif Capital Management LLC boosted its stake in shares of Bio-Rad Laboratories by 1.9% during the fourth quarter. Yousif Capital Management LLC now owns 2,775 shares of the medical research company's stock valued at $896,000 after purchasing an additional 51 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new stake in shares of Bio-Rad Laboratories during the fourth quarter valued at about $42,000. 65.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on BIO shares. UBS Group lifted their price target on Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a "buy" rating in a research note on Friday, February 16th. StockNews.com raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday. Royal Bank of Canada cut their price target on Bio-Rad Laboratories from $484.00 to $480.00 and set an "outperform" rating on the stock in a research note on Friday, February 16th. Finally, Citigroup lowered Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and cut their price target for the company from $400.00 to $365.00 in a research note on Wednesday, April 3rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of "Moderate Buy" and a consensus price target of $468.00.

Bio-Rad Laboratories Trading Up 0.1 %

Shares of BIO traded up $0.34 during mid-day trading on Friday, reaching $275.94. 179,207 shares of the company were exchanged, compared to its average volume of 200,184. Bio-Rad Laboratories, Inc. has a 52 week low of $261.59 and a 52 week high of $473.50. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.34 and a current ratio of 5.83. The stock has a market capitalization of $7.87 billion, a PE ratio of -12.84 and a beta of 0.87. The business has a 50 day simple moving average of $324.94 and a two-hundred day simple moving average of $317.24.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Thursday, February 15th. The medical research company reported $3.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.17. The company had revenue of $681.18 million during the quarter, compared to the consensus estimate of $685.00 million. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The firm's revenue was down 6.7% compared to the same quarter last year. During the same period last year, the company earned $3.31 earnings per share. On average, analysts predict that Bio-Rad Laboratories, Inc. will post 10.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 3,000 shares of Bio-Rad Laboratories stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total value of $1,008,000.00. Following the completion of the sale, the executive vice president now directly owns 6,942 shares in the company, valued at $2,332,512. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 17.06% of the stock is currently owned by corporate insiders.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.